A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
2026年9月2日 更新者:GlaxoSmithKline
A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-Sensitive Ovarian Cancer
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer.
The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.
調査の概要
状態
まだ募集していません
条件
研究の種類
介入
入学 (推定)
690
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:US GSK Clinical Trials Call Center
- 電話番号:877-379-3718
- メール:GSKClinicalSupportHD@gsk.com
研究連絡先のバックアップ
- 名前:EU GSK Clinical Trials Call Center
- 電話番号:+44 (0) 20 89904466
- メール:GSKClinicalSupportHD@gsk.com
研究場所
-
-
-
Hokkaido、日本、003-0804
- GSK Investigational Site
-
コンタクト:
- US GSK Clinical Trials Call Center
- 電話番号:877-379-3718
- メール:GSKClinicalSupportHD@gsk.com
-
コンタクト:
- EU GSK Clinical Trials Call Centre
- 電話番号:+44 (0) 20 8990 4466
- メール:GSKClinicalSupportHD@gsk.com
-
主任研究者:
- Satomi Aoyama
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed Consent Form (ICF).
- Has epithelial ovarian, primary peritoneal, or fallopian-tube cancer with a histologically confirmed diagnosis of high grade serous, high grade endometrioid, clear cell carcinoma, or carcinosarcoma.
Has recurrent or progressive disease after completion of at least 1 and a maximum of 2 previous lines of systemic anticancer therapy. Recurrent or progressive disease should be determined based on radiographic assessment according to RECIST 1.1 per investigator and/or clinical assessment of disease progression by investigator. Prior lines of therapy are defined as follows:
- Adjuvant ± neoadjuvant is considered one line of therapy.
- Maintenance therapy (e.g., bevacizumab, Poly ADP-ribose polymerase inhibitor [PARPi]) will be considered as part of the preceding line of therapy (i.e., not counted independently).
- Therapy changed to another agent in the same class due to toxicity, in the absence of progression, will be considered as part of the same line (i.e., not counted independently).
- Unplanned addition or switching to a new drug in a different class is considered a separate line of therapy
- Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance.
- Has platinum-sensitive disease and is suitable for platinum doublet chemotherapy with bevacizumab for the treatment of recurrent disease. Platinum sensitive disease is defined as recurrent or progressive disease >6 months after last dose of platinum-based chemotherapy.
- Has documented results of local testing (compliant to local regulations) for tumor and/or germline Breast Cancer Gene (BRCA1 and BRCA2) mutation. Participants with a known tumor or germline deleterious BRCA1 or BRCA2 mutation must have previously received PARPi maintenance therapy, alone or in combination with bevacizumab, if the participant was considered a candidate for this treatment and the treatment is locally available.
- Has provided a Formalin Fixed Paraffin Embedded (FFPE) tumor tissue sample sufficient for the central assessment of B7 homolog 4 protein (B7-H4) expression, with the result of B7-H4 expression testing available prior to the date of randomization.
- Is willing to use adequate contraception. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
A female participant is eligible to participate if they are not pregnant or breastfeeding, and 1 of the following conditions applies:
- Is a Participant of Non-Childbearing Potential (PONCBP). OR
- Is a Participant of Childbearing Potential (POCBP) and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency, 30 days prior to Cycle 1 Day 1 (C1D1) and during the study intervention period and for at least 8 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
- A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.
- Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and in this protocol.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has adequate organ function.
Exclusion Criteria:
- Plans to undergo interval secondary cytoreductive surgery for recurrent PSOC during induction therapy (platinum doublet and bevacizumab).
- Has a malignancy (except disease under study) that has progressed or required active treatment within the past 36 months prior to the date of randomization, except for basal cell or squamous cell carcinomas of the skin or in situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease, or that is otherwise considered cured by the investigator.
- Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
- Has untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed (e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases). Participants with previously treated and clinically stable brain/CNS metastases and who have completed all corticosteroid therapy for ≥14 days prior to the date of C1D1 are not excluded from participation.
- Has any evidence of current Interstitial Lung Disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis.
- Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to Grade ≤1 or to the baseline status preceding prior therapy, excluding alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, Grade 2 neuropathy or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.
- Has any serious and/or unstable medical condition (including infection) or any serious and/or unstable psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.
- Has clinically significant wound healing complications or incompletely healed wounds.
- Has a history or evidence of gastrointestinal perforation, tracheoesophageal fistula, or any Grade 4 fistula; has gastrointestinal fistula, visceral fistula, or abdominal abscess within 6 months prior to the date of C1D1; has osteonecrosis of the jaw.
- Has evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on computed tomography (CT) scan or clinical symptoms of bowel obstruction.
- Has clinically significant bleeding symptoms, significant bleeding tendency, or bleeding tumors within 30 days prior to the date of C1D1.
- Has congenital bleeding diathesis, acquired coagulopathy, recent pulmonary hemorrhage/hemoptysis (>2.5 mL of red blood or a half teaspoon) within 3 months prior to the date of C1D1.
- Has had any major surgery within 28 days prior to the date of C1D1 or history of focal radiotherapy within 21 days prior to the date of C1D1.
- Has received treatment with an investigational agent within 30 days prior to the date of C1D1.
- Has ever received prior therapy with topoisomerase 1 inhibitor [Topo1i] (e.g., topotecan) or antibody-Drug Conjugate (ADC) with a Topo1i warhead, or B7-H4 targeted therapy.
- Has received treatment with any cytotoxic chemotherapy drugs or other antitumor drugs (including endocrine therapy, molecular targeted therapy, immunotherapy or biotherapy) within 30 days or 5 half-lives, whichever is shorter, prior to the date of C1D1; or need to continue these drugs during study participation.
- Has received treatment with inhibitors of P-glycoprotein (P-gp), or Breast Cancer Resistant Protein (BCRP), or Organic Anion Transporting Polypeptides 1B1/1B3 (OATP1B1/1B3) within 7 days prior to the date of C1D1. Has received treatment with inducers of P-gp within 14 days prior to the date of C1D1.
- Has received any live vaccine within 30 days prior to the date of C1D1.
- Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days prior to date of C1D1.
- Has a history within 12 months prior to screening of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure, or clinically significant arrhythmia not controlled by standard of care therapy.
- Has baseline Left Ventricular Ejection Fraction (LVEF) <50% or less than institutional lower limit of normal.
- Has clinically significant abnormal blood pressure according to investigator assessment, or inadequately treated and uncontrolled hypertension including history of hypertensive crisis; hypertensive encephalopathy; or adjustment of antihypertensive medications due to poor blood pressure control within 14 days prior to the date of C1D1.
- Has a history of nephrotic syndrome or Grade 3 proteinuria.
- Meets the following criteria for proteinuria during screening assessments: ≥2+ proteinuria on urine dipstick and 24-hour urine collection demonstrating ≥1 g of urine protein in 24 hours.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Mocertatug rezetecan (Mo-Rez) + Bevacizumab
Participants will receive Mo-Rez + bevacizumab.
|
Bevacizumab will be administered
Mocertatug rezetecan will be administered
|
|
アクティブコンパレータ:Platinum doublet + Bevacizumab
Participants will receive platinum doublet chemotherapy (carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin [PLD]) and bevacizumab, followed by bevacizumab maintenance therapy.
|
カルボプラチンが投与されます
パクリタキセルが投与されます
PLDが投与されます
ジェムシタビンが投与されます
Bevacizumab will be administered
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS) by BICR
時間枠:Up to approximately 191 weeks
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first.
|
Up to approximately 191 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:Up to approximately 343 weeks
|
OS is defined as the time from the date of randomization to the date of death due to any cause.
|
Up to approximately 343 weeks
|
|
PFS by investigator assessment
時間枠:Up to approximately 343 weeks
|
PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first.
|
Up to approximately 343 weeks
|
|
Time to Second Progression (PFS2)
時間枠:Up to approximately 343 weeks
|
PFS2 is defined as the time from the date of randomization to the date of first documented investigator-assessed clinical or radiographical progression following the first subsequent anticancer therapy and after the progression event used for the primary variable PFS, or death from any cause, whichever occurs first.
|
Up to approximately 343 weeks
|
|
Objective response rate (ORR) by investigator assessment
時間枠:Up to approximately 343 weeks
|
ORR is defined as the percentage of participants with a complete response (CR) or partial response (PR) per RECIST 1.1 by investigator assessment.
|
Up to approximately 343 weeks
|
|
Duration of Response (DOR) by investigator assessment
時間枠:Up to approximately 343 weeks
|
DOR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by investigator assessment to the date of first documented PD per RECIST 1.1 by investigator assessment or death due to any cause, whichever occurs first.
|
Up to approximately 343 weeks
|
|
ORR by BICR
時間枠:Up to approximately 343 weeks
|
ORR is defined as the percentage of participants with a CR or PR per RECIST 1.1 by BICR.
|
Up to approximately 343 weeks
|
|
DOR by BICR
時間枠:Up to approximately 343 weeks
|
DOR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by BICR assessment to the date of first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.
|
Up to approximately 343 weeks
|
|
Time to first subsequent therapy (TFST)
時間枠:Up to approximately 343 weeks
|
TFST is defined as the time from the date of randomization to the date of initiation of subsequent therapy or death from any cause, whichever occurs first.
|
Up to approximately 343 weeks
|
|
Time to second subsequent therapy (TSST)
時間枠:Up to approximately 343 weeks
|
TSST is defined as the time from the date of randomization to the date of initiation of second subsequent therapy or death from any cause, whichever occurs first.
|
Up to approximately 343 weeks
|
|
Number of participants with Treatment-emergent adverse event (TEAEs), Adverse event of special interest (AESIs) and Treatment-emergent serious adverse event (TESAEs)
時間枠:Up to approximately 343 weeks
|
Up to approximately 343 weeks
|
|
|
Number of participants with TEAEs leading to dose modifications or study intervention discontinuation
時間枠:Up to approximately 343 weeks
|
Up to approximately 343 weeks
|
|
|
Number of participants with changes in vital signs, laboratory tests (hematology and clinical chemistry), and Electrocardiogram (ECG)
時間枠:Up to approximately 343 weeks
|
Up to approximately 343 weeks
|
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score
時間枠:Up to approximately 343 weeks
|
The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.
The following domains will be measured: Global health status (GHS)/ Quality of Life (QoL), physical functioning, role functioning.
Participants responses on these items are averaged and then transformed to scores, ranging from 0 to 100.
Higher score indicates better functioning or a better .
overall state of health.
|
Up to approximately 343 weeks
|
|
Change from baseline in EORTC QLQ-Ovarian Cancer Module (OV28) score
時間枠:Up to approximately 343 weeks
|
The EORTC QLQ-OV28 includes a 28-item questionnaire for evaluating ovarian cancer-specific symptoms and concerns in participants of cancer clinical studies.
These include items that assess symptoms in the abdominal/gastrointestinal domain.
Scores are averaged and transformed to a 0 to 100 scale; higher scores indicate a greater symptom burden, while lower scores reflect fewer symptoms.
|
Up to approximately 343 weeks
|
|
Time to deterioration (TTD) of EORTC QLQ-C30
時間枠:Up to approximately 343 weeks
|
TTD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on any of the following EORTC QLQ-C30 domains: physical functioning, role functioning and Global Health Status (GHS)/ Quality of Life (QoL).
|
Up to approximately 343 weeks
|
|
Time to deterioration (TTD) of EORTC QLQ-OV28
時間枠:Up to approximately 343 weeks
|
TTD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the abdominal /gastrointestinal symptom domain of the EORTC QLQ-OV28.
|
Up to approximately 343 weeks
|
|
Serum concentration of Mo-Rez
時間枠:Up to approximately 343 weeks
|
Up to approximately 343 weeks
|
|
|
Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Mo-Rez
時間枠:Up to approximately 343 weeks
|
Up to approximately 343 weeks
|
|
|
Titers of ADA against Mo-Rez
時間枠:Up to approximately 343 weeks
|
Up to approximately 343 weeks
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年9月22日
一次修了 (推定)
2030年5月21日
研究の完了 (推定)
2033年4月22日
試験登録日
最初に提出
2026年6月29日
QC基準を満たした最初の提出物
2026年6月29日
最初の投稿 (実際)
2026年7月6日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月3日
QC基準を満たした最後の更新が送信されました
2026年9月2日
最終確認日
2026年9月1日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 内分泌系疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 生殖器疾患、女性
- 内分泌腺腫瘍
- 卵巣疾患
- 付属器疾患
- 性器腫瘍、女性
- 性腺疾患
- 卵巣腫瘍
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 調整錯体
- タキソイド
- シクロデカン
- Diterpenes
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ベバシズマブ
- ゲムシタビン
- カルボプラチン
- パクリタキセル
- リポソームドキソルビシン
その他の研究ID番号
- 224040
- 2025 (米国 NIH グラント/契約:Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 2025-523366-24-00 (Ctis)
- GOG- 3136 (その他の識別子:Gynaecologic Oncology Group (GOG))
- ENGOT-ov99 (その他の識別子:European Network of Gynaecological Oncological Trial Groups (ENGOT))
- APGOT-OV19 (その他の識別子:Asia-Pacific Gynaecologic Oncology Trials Group (APGOT))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents.
Data sharing is subject to certain criteria, conditions, and exceptions.
For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD 共有時間枠
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共有アクセス基準
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
はい
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。